Novartis to cut more than 440 jobs in Britain

Swiss pharmaceuticals giant Novartis said Wednesday it aimed to slash more than 440 jobs in Britain, blaming industry-wide difficulties.

Novartis is considering closing its manufacturing site in Horsham, West Sussex, which would lead to the evaporation of 371 jobs, the told AFP in an email, confirming a report by the FierceBiotech website.

The closure was needed as Novartis attempts to adapt to "a challenging healthcare marketplace," it said, stressing that the decision was still subject to consultations with employees and final approval by its UK board.

"We understand that this will be a difficult time for potentially affected employees, their families and the wider Horsham community given the links the company has in the area," Novartis said, vowing to do its utmost to "make the process as straightforward and smooth as possible."

Two years ago, Novartis announced plans to halt manufacturing at the site and to cut staff numbers there from 950 to 450 people, but the group said Wednesday it now also aimed to close a unit dedicated to .

Novartis also said that cuts at its UK pharmaceuticals division in Frimley, Surrey, could impact another 72 .

The company currently employs more than 3,000 people in Britain.

add to favorites email to friend print save as pdf

Related Stories

Novartis announces 2,000 job losses, profits up

Oct 25, 2011

Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

Recommended for you

New system targets germs in donated blood plasma

17 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.